Federal Circuit finds Myriad patents invalid

December 18, 2014 – Federal Circuit Judges Timothy Dyk, Sharon Prost, and Raymond Clevenger issued a decision affirming the District of Utah Judge Robert J. Shelby’s decision denying Plaintiffs-Appellants University of Utah Research Foundation, The Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, Endorecherche, Inc, and Myriad Genetics, Inc.’s motion for a preliminary injunction against Defendant-Appellee Ambry Genetics Corp. and finding three of Myriad’s breast and ovarian cancer test patents, U.S. Patent Nos. 5,753,441; 5,747,282; and 5,837,492, invalid for claiming patent-ineligible subject matter. The case is captioned In re: BRCA1- and BRCA2-Based Hereditary Cancer Test Patent Litigation, 14-1361 and 14-1366.

By: Margaret A. Scoolidge

View Attachment (PDF)